DUBLIN, March 28, 2024 /PRNewswire/ -- The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to
ResearchAndMarkets.com's offering.
Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.
Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician's Office or even the Home?
Point of Care testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks.
The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size for five years.
1.1 Strategic Situation Analysis
1.2 Guide for Executives, Marketing and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics at the Point of Care?
2.2 The Diagnostics Revolution
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3 Instrumentation, Automation and Diagnostic Trends
3.1 Instrumentation and Automation
3.1.1 Traditional Automation and Centralization
3.1.2 The New Automation, Decentralization and Point Of Care
3.1.3 Instruments Key to Market Share
3.1.4 Bioinformatics Plays a Role
3.1.6 Next Generation Sequencing Fuels a Revolution
3.1.7 NGS Impact on Pricing
3.1.8 Whole Genome Sequencing, A Brave New World
3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Chemical/Reagent Supplier
4.1.6 Independent Clinical Laboratory
4.1.7 Public National/regional Laboratory
4.1.8 Hospital Laboratory
4.1.9 Physicians Office Lab (POLS)
4.1.11 Certification Body.
4.2 The Clinical Laboratory Market Segments
4.2.1 Traditional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.3.1 Hospital Testing Share
4.3.2.1 Hospital vs. Central Lab
4.3.3 Physician Office Lab's
4.3.4 Physician's and POCT
5 Profiles of Key MDx Companies
5.3 Accelerate Diagnostics
5.14 Autonomous Medical Devices
5.21 bioMerieux Diagnostics
5.27 Curetis N.V./Curetis GmbH
5.29 Diagenode Diagnostics
5.50 LightDeck Diagnostics
5.72 Primerdesign (Novacyt)
5.83 Siemens Healthineers
6.1 Factors Driving Growth
6.1.1 New Genotypes Creating New Markets
6.1.2 Aging Population a Boon for All Diagnostics
6.1.3 Developing World Driving ID Dx Growth
6.1.4 Point of Care - Why Centralization is Losing Steam
6.2 Factors Limiting Growth
6.2.2 Infectious Disease is Declining
6.2.4 Economic Growth improves Living Standards
7 Molecular Dx - Infectious Disease Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.3 Llusern Scientific to Launch POC MDx UTI Panel
7.4 Altratech Enters POC MDx Testing Space with Unique Tech
7.5 BioMerieux SpotFire MDx POC System Leverages Novel Approach
7.6 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System 7.9 NanoDx Prepares for Point-of-Care Commercialization
7.10 Paragraf to Study New POC Test to Guide Antibiotic Selection
7.11 MicroGEM to Expand 30-Minute RT-PCR System
7.12 Startup Detect to Roll Out Next-Gen Molecular Instrument
7.13 Diagnostics for the Real World Third-Generation POC Platform
7.15 Cue Health Targets DTC Market in 2022
7.16 Grip Molecular Developing Home Respiratory Panel
7.17 Mainz Biomed Developing Home ColoAlert Assay
7.18 MFB Fertility Closes Series A Financing Round
7.19 Home Test Company Prenetics to go Public
7.20 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio 7.21 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
7.24 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
7.25 Hologic to Acquire Mobidiag
7.26 Lucira Health Focuses on User Friendly Approach to Home Testing 7.28 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
7.31 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
7.33 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection 7.34 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
7.36 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
7.37 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
For more information about this report visit https://www.researchandmarkets.com/r/xa3p6x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets